mutLBSgeneDB |
Gene summary for NLGN4X |
Gene summary |
Basic gene Info. | Gene symbol | NLGN4X |
Gene name | neuroligin 4, X-linked | |
Synonyms | ASPGX2|AUTSX2|HLNX|HNL4X|NLGN4 | |
Cytomap | UCSC genome browser: Xp22.33 | |
Type of gene | protein-coding | |
RefGenes | NM_001282145.1, NM_001282146.1,NM_020742.3,NM_181332.2, | |
Description | neuroligin-4, X-linked | |
Modification date | 20141219 | |
dbXrefs | MIM : 300427 | |
HGNC : HGNC | ||
Ensembl : ENSG00000146938 | ||
HPRD : 02336 | ||
Vega : OTTHUMG00000021093 | ||
Protein | UniProt: Q8N0W4 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_NLGN4X | |
BioGPS: 57502 | ||
Pathway | NCI Pathway Interaction Database: NLGN4X | |
KEGG: NLGN4X | ||
REACTOME: NLGN4X | ||
Pathway Commons: NLGN4X | ||
Context | iHOP: NLGN4X | |
ligand binding site mutation search in PubMed: NLGN4X | ||
UCL Cancer Institute: NLGN4X | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0090394 | negative regulation of excitatory postsynaptic membrane potential | 19726642 | GO:0097105 | presynaptic membrane assembly | 19726642 |
Top |
Ligand binding site mutations for NLGN4X |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | Q105 | Q105K | HNSC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for NLGN4X |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | Q105 | Q105K | -0.650124 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for NLGN4X from PDB |
Top |
Differential gene expression and gene-gene network for NLGN4X |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for NLGN4X |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0004352 | Autistic Disorder | 26 | Biomarker, GeneticVariation |
umls:C0008074 | Child Development Disorders, Pervasive | 1 | Biomarker |
umls:C1136249 | Mental Retardation, X-Linked | 1 | Biomarker, GeneticVariation |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for NLGN4X |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of NLGN4X go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 5AX | 2-(ACETYLAMINO)-1,5-ANHYDRO-2-DEOXY-D-GLUCITOL | 2wqz | A | Q105 |
Top |
Conservation information for LBS of NLGN4X |
Multiple alignments for Q8N0W4 in multiple species |
LBS | AA sequence | # species | Species |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |